Debt-to-equity of Summit Therapeutics Inc. from 31 Mar 2021 to 31 Dec 2025
- Taxonomy & unit
- ratio: x
- Description
- Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's debt by its shareholder equity.
- Summary
-
Summit Therapeutics Inc. quarterly Debt-to-equity in x history and change rate from 31 Mar 2021 to 31 Dec 2025.
- Summit Therapeutics Inc. Debt-to-equity for the quarter ending 31 Dec 2025 was 0.18x, a 50% decline year-over-year.
Debt-to-equity, Quarterly (x)
Debt-to-equity, YoY Quarterly Change (%)
Summit Therapeutics Inc. Quarterly Debt-to-equity (x)
| Period | Value | YoY Chg | Change % | Date |
|---|---|---|---|---|
| Q4 2025 | 0.18x | -0.18x | -50% | 31 Dec 2025 |
| Q3 2025 | 0.19x | -0.44x | -70% | 30 Sep 2025 |
| Q2 2025 | 0.15x | -1.11x | -88% | 30 Jun 2025 |
| Q1 2025 | 0.22x | -1.23x | -85% | 31 Mar 2025 |
| Q4 2024 | 0.37x | -0.76x | -67% | 31 Dec 2024 |
| Q3 2024 | 0.62x | -1.25x | -67% | 30 Sep 2024 |
| Q2 2024 | 1.26x | -0.3x | -19% | 30 Jun 2024 |
| Q1 2024 | 1.45x | -0.18x | -11% | 31 Mar 2024 |
| Q4 2023 | 1.12x | -0.62x | -36% | 31 Dec 2023 |
| Q3 2023 | 1.87x | +1.42x | +318% | 30 Sep 2023 |
| Q2 2023 | 1.56x | +1.05x | +207% | 30 Jun 2023 |
| Q1 2023 | 1.63x | +1.27x | +348% | 31 Mar 2023 |
| Q4 2022 | 1.75x | +1.32x | +306% | 31 Dec 2022 |
| Q3 2022 | 0.45x | +0.03x | +7.7% | 30 Sep 2022 |
| Q2 2022 | 0.51x | +0.03x | +5.3% | 30 Jun 2022 |
| Q1 2022 | 0.36x | -0.22x | -38% | 31 Mar 2022 |
| Q4 2021 | 0.43x | 31 Dec 2021 | ||
| Q3 2021 | 0.42x | 30 Sep 2021 | ||
| Q2 2021 | 0.48x | 30 Jun 2021 | ||
| Q1 2021 | 0.59x | 31 Mar 2021 |
* An asterisk sign (*) next to the value indicates that the value is likely invalid.